• The relatively high availability of resources (especially non-human primates) and relatively low costs make China an interesting opportunity for drug safety managers to better optimize their work productivity including faster study scheduling & turn-around times, and ways to stretch their budget dollars.
  
  
• There is a rapid emergence of preclinical testing facilities in China due to a number of factors including: supportive government policies, rapid economic growth, significant government and private sector investment to create preclinical safety capacity, a large pool of scientific and technical employees to recruit into the industry, and large numbers of western trained “returnees” with significant industry experience.
  
  
• Involvement of western pharma in the form of study over-site and guidance will not only accelerate the availability of full GLP compliant facilities, but enable those centers to expand more rapidly to a size needed to support large clients.

  Download full Project Description                                                                       Contact Us

Previous Page    Back to Project Description    Next Page